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Infectious diseasesa b s t r a c t
The second Infectious Intestinal Diseases study (IID2) estimated the incidence of norovirus in the UK at
47/1000 population (three million cases annually). Clinically significant norovirus was defined using a
cycle threshold (ct) value of <30; a more stringent cut-off than used in diagnostic laboratories. The
low infectious dose of norovirus means asymptomatic individuals potentially contribute to ongoing
transmission. Using a less stringent but diagnostically relevant threshold increases the estimation of
the population burden of norovirus infection by around 26% to 59/1000 person years (95% CI 52.32–
64.98), equating to 3.7 million norovirus infections annually (3.3–4.1 million). With possible vaccines
on the horizon for norovirus, having a good estimate of the total burden of norovirus infection, as well
as symptomatic disease will be useful in helping to guide vaccination policy when candidate vaccines
become available.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Norovirus is the commonest cause of gastrointestinal disease
across all age groups worldwide [1]. The majority of cases experi-
ence a mild, self-limiting illness and few cases tend to consult pri-
mary healthcare. Those that do might not be sampled, leading to
huge under-diagnosis and under-reporting [2]. The Second Study
of Infectious Intestinal Disease in the community (IID2 study) in
the UK estimated the community incidence of norovirus to be
47/1000 population, which equates to around three million cases
a year [3], at a cost to cases and the health service of up to
£106million (around US $178 million at that time) [4].
The IID2 study is one of only two large population based cohort
studies in Europe that provided disease estimates using molecular
methods for detecting norovirus in stool samples [3,5]. In the IID2
study clinically significant norovirus was defined by using a cycle
threshold (ct) value of 30 or less [3]. This was a more stringent
cut-off than would normally be employed in clinical diagnostic
laboratories. Norovirus detected in stool samples above a ct value
of 30 was considered to reflect asymptomatic carriage or sub-
clinical infections [6]. Thus the estimates of norovirus using a ct
value of 30 or less from the IID2 study equated to the burden of
symptomatic disease.The role of asymptomatic carriage of norovirus, particularly in
causing outbreaks or ongoing transmission events, is unclear [7].
The very low infectious dose of norovirus makes it a distinct possi-
bility that asymptomatic individuals contribute to ongoing trans-
mission but the evidence is mixed. In one large hospital outbreak
there was no apparent correlation between ct value and symptom
duration or onward transmission [8] and a study of outbreaks in
healthcare settings found asymptomatic healthcare workers were
rarely involved in transmission [9]. However there are documented
outbreaks that support this hypothesis [10,11]. Given the potential
public health significance of asymptomatic carriage we have re-
assessed the total burden of circulating norovirus in the UK popu-
lation by using the higher ct value of <40 for norovirus.2. The study
The IID2 study has been described in detail elsewhere [3,12,13].
Briefly, one of the components of the study comprised a prospec-
tive cohort study where randomly selected healthy people of all
ages were enrolled from randomly selected general practices
(GP) across the United Kingdom. Volunteers were followed up at
weekly intervals for one year to identify any symptoms of infec-
tious intestinal disease (IID).
People who fulfilled the case definition i.e. people who devel-
oped clinically significant vomiting (more than once in a 24 h per-
iod, or it caused incapacity or was accompanied by other
symptoms) or loose stools for a period of less than two weeks,
Table 1
Age-specific burden of total circulating norovirus in the United Kingdom population, 2009.
Age group No. infected Person years Infections/1000 person years (95%CI) Infections/1000 person years from IID2 studya
All ages 276 4658.6 59.64 (52.3–64.9) 47 (39.1–56.5)
<1 6 26.9 238.02 (186.1–446.6) 178.2 (70.5–450.0)
1–4 34 190.8 179.83 (141.5–241.1) 137.3 (92.6–203.4)
5–14 28 424.1 66.65 (40.1–101.4) 59.6 (36.8–96.5)
15–64 126 2647.8 47.55 (34.7–58.2) 39.0 (31.3–48.7)
65+ 45 1369.1 32.66 (20.4–45.3) 27.7 (19.6–39.1)
P5 40 217.6 183.82 (147.1–266.5) 142.6 (99.8–203.9)
65 199 4441.0 44.81 (29.7–66.2) 37.6 (31.5–44.7)
a Published in: [16].
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been symptom free in the preceding three weeks, were asked to
complete a clinical symptom questionnaire. The definition of vom-
iting excluded conditions associated with non-infectious causes
such as pyloric stenosis or morning sickness. All cases were asked
to provide a stool sample for microbiological testing. Diagnosis of
clinically relevant norovirus used real time quantitative reverse
transcription polymerase chain reaction (RT-PCR) with a cycle
threshold of less than 30. Here, however, we use the assay analyt-
ical cut off of less than 40 to estimate the likely total burden of cir-
culating norovirus.
For norovirus-associated infection the incidence was derived by
dividing the number of cases with a PCR-confirmed diagnosis, by
the number of person years at risk in the cohort study. For specific
age groups this is the number of cases in each age group divided by
the number of person years at risk in each age group.
Not all participants submitted a stool specimen for diagnosis. To
establish the status of the individual for norovirus-associated
infection where a sample was missing (35% of cases), it was
derived by imputation. The imputation method used Multiple
Imputation by Chained Equations and modelled whether the indi-
vidual had a norovirus-associated infection as a function of age, sex
and whether they exhibited any of five symptoms, vomiting, diar-
rhoea, bloody diarrhoea or fever. The imputation process created
20 datasets and burden of infection was estimated as the average
number of infected individuals from the 20 imputed datasets.
The number of people affected varied between the imputed data-
sets. In order to account for this variation, the imputation method
was conducted 1000 times and the average values of the 20
imputed data sets were calculated on each iteration. The 5th and
95th centile of these averages were used for the credibility interval.
The overall incidence rate and those for the age groups; under
1 year, 1–4 years, 5–14 years 15–64 years and 65 years and above
were calculated. The person years at risk from the IID2 study were
used as denominators.
Statistical analysis was conducted using R statistical software
[14] using the MICE package [15].
A favourable ethical opinion to perform the IID2 Study was
granted by the NHS North West Research Ethics Committee (07/
MRE08/5) and all participants gave informed written consent prior
to being enrolled in the study. No ethical review was required for
this secondary analysis of fully anonymised data.
The overall burden of infection for norovirus-associated infec-
tions from the cohort study was 59 per 1000 person years (95%
CI 52.32–64.98). Using the Office for National Statistics (ONS)
mid 2009 population estimate for the UK, this equates to 3.7 mil-
lion people infected with norovirus in a year (3.3–4.1 million).
The highest rates were in the youngest age groups (Table 1). The
incidence in those aged less than 1 year was 238 per 1000 person
years (186.11–446.65) and those aged 1–4 years the rate was 180
per 1000 person years (141.53–241.12). For children aged less than5 years the rate was four times higher than all other age groups.
The results of this study suggest that around 6% of the population
and around 18% of children aged less than five years are affected by
norovirus each year. The number of infections estimated was low
particularly in the youngest age groups and this is reflected in
the wide ranges in the estimated values.3. Conclusions
The IID2 study provided estimates of clinically relevant noro-
virus disease, and suggested that around 3 million cases occur each
year. This re-analysis, using a less stringent ct value of 40, adds
around 800,000 cases of infection bringing the annual total of cir-
culating norovirus closer to 4 million cases in the UK. This differ-
ence is important, especially in light of the candidate norovirus
vaccines that are being developed. It is not yet clear how a vaccine
might be implemented (if at all) and so to have good estimates of
the total burden of norovirus infection, as well as symptomatic dis-
ease [16], should be useful in helping to guide vaccination policy
when the time comes [17].
Key strengths of the IID2 study were its prospective nature,
with active of follow-up and sampling of people declaring symp-
toms of IID, and the use of RT-PCR for confirming the presence of
norovirus. Important limitations were a relatively low overall par-
ticipation rate, although people who enrolled in the study tended
to comply with the study procedures (including providing sam-
ples), and the lack of a formal control group. A limitation of the
RT-PCR method is that it cannot distinguish between infectious
and non-infectious virus.
In conclusion we have found that using a less stringent but
diagnostically relevant threshold increases the estimation of the
population burden of norovirus infection by around 26%. The addi-
tional burden in children aged under 5 was almost 30%. Given the
possibility of a vaccine on the horizon [17], and the need for more
robust estimates of the number of infections for policy makers, this
study shows that the additional burden is greater in young
children.Funding
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